Autolus Therapeutics Files 8-K

Ticker: AUTL · Form: 8-K · Filed: 2025-04-23T00:00:00.000Z

Sentiment: neutral

Topics: reporting, financial-statements

TL;DR

Autolus filed an 8-K with financial statements and exhibits. No major news.

AI Summary

Autolus Therapeutics plc filed an 8-K on April 23, 2025, reporting on financial statements and exhibits. The company, incorporated in England and Wales, is involved in the biological products sector, specifically focusing on cell therapy development. This filing does not appear to contain specific financial figures or material events beyond the standard reporting of financial statements and exhibits.

Why It Matters

This filing indicates Autolus Therapeutics plc is fulfilling its reporting obligations by submitting financial statements and exhibits, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine submission of financial statements and exhibits, not indicating any new risks or material changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Autolus Therapeutics plc?

The primary purpose of this 8-K filing is to report on financial statements and exhibits as of April 23, 2025.

When was the report filed by Autolus Therapeutics plc?

The report was filed as of April 23, 2025.

In which jurisdiction was Autolus Therapeutics plc incorporated?

Autolus Therapeutics plc was incorporated in England and Wales.

What is the principal executive office address for Autolus Therapeutics plc?

The principal executive office is located at The Mediaworks, 191 Wood Lane, London, W12 7FP, United Kingdom.

Does this filing disclose any specific financial results or material events?

This filing primarily reports on financial statements and exhibits and does not appear to disclose specific financial results or new material events beyond standard reporting requirements.

From the Filing

0001730463-25-000022.txt : 20250423 0001730463-25-000022.hdr.sgml : 20250423 20250423062624 ACCESSION NUMBER: 0001730463-25-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250423 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250423 DATE AS OF CHANGE: 20250423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 25859156 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 autl-20250423.htm 8-K autl-20250423 0001730463 FALSE 0001730463 2025-04-23 2025-04-23 0001730463 sic:Z8880 2025-04-23 2025-04-23 0001730463 us-gaap:CommonClassAMember 2025-04-23 2025-04-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share* * The Nasdaq Stock Market LLC * * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provi

View on Read The Filing